Literature DB >> 23258148

A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy.

Jimena Rojas1, Itziar Fernandez, Jose C Pastor, Robert E Maclaren, Yashim Ramkissoon, Steven Harsum, David G Charteris, Jan C Van Meurs, Sankha Amarakoon, Jose M Ruiz-Moreno, Amandio Rocha-Sousa, Maria Brion, Angel Carracedo.   

Abstract

PURPOSE: Proliferative vitreoretinopathy (PVR) is still the major cause of failure of retinal detachment (RD) surgery and although the risk for developing this complication is associated with some clinical characteristics, the correlation is far from absolute, raising the possibility of genetic susceptibility. The objective of this study was to analyze the genetic contribution to PVR in patients undergoing RD surgery, the Retina 4 Project.
METHODS: A candidate gene association study was conducted in 2006 in a Spanish population of 450 patients suffering from primary rhegmatogenous RD. Replication was carried out in a larger population undergoing RD surgery at several European centers among 546 new patients. Single nucleotide polymorphism (SNP) of 30 genes known to be involved with inflammation were analyzed. For replication stage, those genes previously detected as significantly associated with PVR were genotyped. Distribution of allelic and haplotypic frequencies in case and control group were analyzed. Single and haplotypic analysis were assessed. The Rosenberg two-stage method was used to correct for single and multiple analyses.
RESULTS: After correction for multiple comparisons, four genes were significantly associated with PVR: SMAD7 (P = 0.004), PIK3CG (P = 0.009), TNF locus (P = 0.0005), and TNFR2 (P = 0.019) In the European sample, replication was observed in SMAD7 (P = 0.047) and the TNF locus (P = 0.044).
CONCLUSIONS: These results confirm the genetic contribution to PVR and the implication of SMAD7 and TNF locus in the development of PVR. This finding may have implications for understanding the mechanisms of PVR and could provide a potential new therapeutic target for PVR prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23258148     DOI: 10.1167/iovs.12-10931

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

1.  Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Authors:  Steven Pennock; Luis J Haddock; Shizuo Mukai; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2014-09-26       Impact factor: 4.307

Review 2.  Proliferative Vitreoretinopathy: A Review.

Authors:  Sana Idrees; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2019

3.  Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target.

Authors:  C Nathaniel Roybal; Gabriel Velez; Marcus A Toral; Stephen H Tsang; Alexander G Bassuk; Vinit B Mahajan
Journal:  Am J Ophthalmol       Date:  2017-12-13       Impact factor: 5.258

Review 4.  [Proliferative vitreoretinopathy process-To heal or not to heal].

Authors:  S Grisanti; S Priglinger; L Hattenbach
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

5.  Proliferative vitreoretinopathy and genetic profile.

Authors:  Khalil Ghasemi Falavarjani
Journal:  J Ophthalmic Vis Res       Date:  2013-01

6.  The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy.

Authors:  Rui Zhang; Xin Sun; Bo Niu
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

7.  Functional characterization of rs2229094 (T>C) polymorphism in the tumor necrosis factor locus and lymphotoxin alpha expression in human retina: the Retina 4 project.

Authors:  Salvador Pastor-Idoate; Irene Rodríguez-Hernández; Jimena Rojas; Lucia Gonzalez-Buendia; Santiago Delgado-Tirado; Jose Carlos López; Rogelio González-Sarmiento; Jose C Pastor
Journal:  Clin Ophthalmol       Date:  2017-05-22

8.  Expression of VEGF-A, Otx homeobox and p53 family genes in proliferative vitreoretinopathy.

Authors:  Claudio Azzolini; Ilaria Stefania Pagani; Cristina Pirrone; Davide Borroni; Simone Donati; Muna Al Oum; Diana Pigni; Anna Maria Chiaravalli; Riccardo Vinciguerra; Francesca Simonelli; Giovanni Porta
Journal:  Mediators Inflamm       Date:  2013-10-21       Impact factor: 4.711

9.  The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy.

Authors:  Salvador Pastor-Idoate; Irene Rodríguez-Hernández; Jimena Rojas; Itziar Fernández; María T García-Gutiérrez; José M Ruiz-Moreno; Amandio Rocha-Sousa; Yashin Ramkissoon; Steven Harsum; Robert E MacLaren; David Charteris; Jan C VanMeurs; Rogelio González-Sarmiento; José C Pastor
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

10.  Comparison of SNP Genotypes Related to Proliferative Vitreoretinopathy (PVR) across Slovenian and European Subpopulations.

Authors:  Xhevat Lumi; Mateja M Jelen; Daša Jevšinek Skok; Emanuela Boštjančič; Metka Ravnik-Glavač; Marko Hawlina; Damjan Glavač
Journal:  J Ophthalmol       Date:  2018-05-15       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.